Pravastatin and Sofosbuvir and velpatasvir interaction
Pravastatin and Sofosbuvir and velpatasvir: both prescribing labels describe an interaction that usually calls for monitoring, a dose change, or spacing the doses.
Usually manageable with monitoring or a dose change. Tell your pharmacist you take both.
What the FDA labels say
From the Pravastatin (Pravastatin Sodium) label · effective 2026-08-17
Pravastatin sodium plasma levels can be significantly increased with concomitant administration of inhibitors of OATP1B1.
From the Sofosbuvir and velpatasvir (Vosevi) label · effective 2025-07-14
Pravastatin may be administered with VOSEVI at a dose that does not exceed pravastatin 40 mg. rosuvastatin ↑ rosuvastatin Coadministration of VOSEVI with rosuvastatin may significantly increase the concentration of rosuvastatin which is associated with increased risk of myopathy, including rhabdomyolysis.
HMG-CoA Reductase Inhibitors: pravastatin ↑ pravastatin Coadministration of VOSEVI with pravastatin has been shown to increase the concentration of pravastatin, which is associated with increased risk of myopathy, including rhabdomyolysis.
Increased statin concentrations may increase the risk of myopathy, including rhabdomyolysis.
If higher doses are needed, use the lowest necessary statin dose based on a risk/benefit assessment.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.